FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3183642013> ?p ?o ?g. }

• W3183642013 endingPage "295" @default.
• W3183642013 startingPage "288" @default.
• W3183642013 abstract "In locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin. This study evaluated whether irinotecan/5-fluorouracil (5-FU; mFOLFIRI) was superior to oxaliplatin/5-FU (mFOLFOX) as a second-line treatment in BTC.Patients diagnosed with BTC with disease progression after prior gemcitabine/cisplatin were randomised (1:1) to either mFOLFOX (control arm) or mFOLFIRI (experimental arm). Randomisation was stratified by tumour location (intrahepatic versus extrahepatic versus gallbladder versus ampulla of Vater) and ECOG performance status (0, 1 versus 2). The primary endpoint was the overall survival (OS) rate at 6 months.In total, 120 patients were enrolled and 118 patients were randomised (mFOLFOX n = 59, mFOLFIRI n = 59). The baseline characteristics were well balanced between the two arms. The tumour location was intrahepatic bile duct in 48 patients (40.7%), extrahepatic bile duct in 29 patients (24.6%), gallbladder in 35 patients (29.7%) and ampulla of Vater in 6 patients (5.1%). At a median follow-up duration of 25.8 months, the 6-month OS rate was 54.1% in mFOLFOX and 44.1% in mFOLFIRI (p = 0.677). The median OS was 6.3 months (95% CI, 4.4-8.2) in mFOLFOX and 5.7 months (95% CI, 4.7-6.7) in mFOLFIRI (p = 0.677). The median progression-free survival was 2.8 months (95% CI, 2.3-3.3) in mFOLFOX and 2.1 months (95% CI, 1.1-3.1) in mFOLFIRI (p = 0.974). Of the 101 evaluable patients, the objective response rate and disease control rate were 5.9% and 66.7% in mFOLFOX and 4.0% and 64.0% in mFOLFIRI (p = 0.663 and p = 0.778, respectively). Peripheral neuropathy (37.5% versus 5.2%) and thrombocytopenia (35.7% versus 15.5%) in mFOLFOX and vomiting (19.0% versus 1.8%) and cholangitis (10.3% versus 0.0%) in mFOLFIRI occurred more frequently. No chemotherapy-related death was reported.In the second-line treatment of BTC, mFOLFIRI was not superior to mFOLFOX. However, mFOLFIRI was tolerable and showed comparable efficacy to mFOLFOX. Adverse events were different between the two arms. CLINICALTRIALS.NCT03464968." @default.
• W3183642013 created "2021-08-02" @default.
• W3183642013 creator A5012153148 @default.
• W3183642013 creator A5016948885 @default.
• W3183642013 creator A5023381560 @default.
• W3183642013 creator A5026250495 @default.
• W3183642013 creator A5026612909 @default.
• W3183642013 creator A5044075250 @default.
• W3183642013 creator A5045922502 @default.
• W3183642013 creator A5063462114 @default.
• W3183642013 creator A5077171293 @default.
• W3183642013 creator A5080197428 @default.
• W3183642013 date "2021-09-01" @default.
• W3183642013 modified "2023-10-05" @default.
• W3183642013 title "A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy" @default.
• W3183642013 cites W1903979702 @default.
• W3183642013 cites W1997854400 @default.
• W3183642013 cites W2106550415 @default.
• W3183642013 cites W2115261608 @default.
• W3183642013 cites W2200769448 @default.
• W3183642013 cites W2337387091 @default.
• W3183642013 cites W2403585105 @default.
• W3183642013 cites W2769909737 @default.
• W3183642013 cites W2811258207 @default.
• W3183642013 cites W2996284088 @default.
• W3183642013 cites W3010944770 @default.
• W3183642013 cites W3021696184 @default.
• W3183642013 cites W3024247862 @default.
• W3183642013 cites W3033656623 @default.
• W3183642013 cites W3144916167 @default.
• W3183642013 doi "https://doi.org/10.1016/j.ejca.2021.06.019" @default.
• W3183642013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34303267" @default.
• W3183642013 hasPublicationYear "2021" @default.
• W3183642013 type Work @default.
• W3183642013 sameAs 3183642013 @default.
• W3183642013 citedByCount "14" @default.
• W3183642013 countsByYear W31836420132022 @default.
• W3183642013 countsByYear W31836420132023 @default.
• W3183642013 crossrefType "journal-article" @default.
• W3183642013 hasAuthorship W3183642013A5012153148 @default.
• W3183642013 hasAuthorship W3183642013A5016948885 @default.
• W3183642013 hasAuthorship W3183642013A5023381560 @default.
• W3183642013 hasAuthorship W3183642013A5026250495 @default.
• W3183642013 hasAuthorship W3183642013A5026612909 @default.
• W3183642013 hasAuthorship W3183642013A5044075250 @default.
• W3183642013 hasAuthorship W3183642013A5045922502 @default.
• W3183642013 hasAuthorship W3183642013A5063462114 @default.
• W3183642013 hasAuthorship W3183642013A5077171293 @default.
• W3183642013 hasAuthorship W3183642013A5080197428 @default.
• W3183642013 hasConcept C121608353 @default.
• W3183642013 hasConcept C126322002 @default.
• W3183642013 hasConcept C143998085 @default.
• W3183642013 hasConcept C2776694085 @default.
• W3183642013 hasConcept C2777546739 @default.
• W3183642013 hasConcept C2778239845 @default.
• W3183642013 hasConcept C2780258809 @default.
• W3183642013 hasConcept C2780259306 @default.
• W3183642013 hasConcept C2780840399 @default.
• W3183642013 hasConcept C2780962732 @default.
• W3183642013 hasConcept C526805850 @default.
• W3183642013 hasConcept C71924100 @default.
• W3183642013 hasConcept C90924648 @default.
• W3183642013 hasConceptScore W3183642013C121608353 @default.
• W3183642013 hasConceptScore W3183642013C126322002 @default.
• W3183642013 hasConceptScore W3183642013C143998085 @default.
• W3183642013 hasConceptScore W3183642013C2776694085 @default.
• W3183642013 hasConceptScore W3183642013C2777546739 @default.
• W3183642013 hasConceptScore W3183642013C2778239845 @default.
• W3183642013 hasConceptScore W3183642013C2780258809 @default.
• W3183642013 hasConceptScore W3183642013C2780259306 @default.
• W3183642013 hasConceptScore W3183642013C2780840399 @default.
• W3183642013 hasConceptScore W3183642013C2780962732 @default.
• W3183642013 hasConceptScore W3183642013C526805850 @default.
• W3183642013 hasConceptScore W3183642013C71924100 @default.
• W3183642013 hasConceptScore W3183642013C90924648 @default.
• W3183642013 hasLocation W31836420131 @default.
• W3183642013 hasLocation W31836420132 @default.
• W3183642013 hasOpenAccess W3183642013 @default.
• W3183642013 hasPrimaryLocation W31836420131 @default.
• W3183642013 hasRelatedWork W1523425138 @default.
• W3183642013 hasRelatedWork W2037724349 @default.
• W3183642013 hasRelatedWork W2085978374 @default.
• W3183642013 hasRelatedWork W2100029565 @default.
• W3183642013 hasRelatedWork W2381460883 @default.
• W3183642013 hasRelatedWork W2471989939 @default.
• W3183642013 hasRelatedWork W2516127020 @default.
• W3183642013 hasRelatedWork W2599910524 @default.
• W3183642013 hasRelatedWork W2811271347 @default.
• W3183642013 hasRelatedWork W2910998150 @default.
• W3183642013 hasVolume "154" @default.
• W3183642013 isParatext "false" @default.
• W3183642013 isRetracted "false" @default.
• W3183642013 magId "3183642013" @default.
• W3183642013 workType "article" @default.